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Platelet-denved ndothelial cell growth factor (PD-ECGF) stimulaten chcmotaxts of endothehal cells in wtro and has angiogenic acttvity m vtvo. 
Recenti2¢ PD-ECGF was shown to have thymidine phosphorylase activity. In order to ~tudy po5,~tble thcral~ntte appheation~ of PD-I:COF we 
used a rat model to determine it~ pharmacokinettc~ and tt~sue dtstnbuttoa after intravenou~ injection. [~2~I]PD-ECGF dtsappeared from the plasma 
in a btphasic manner, with estimated distribution and ehmmation half-hves of 17 rain and 7 h, respectively. PD-ECGF was metabolized tnthe liver, 
excreted via the bde, and not accumulat~ an any organ system. The stability and long half-hfe in the cireulatton, together wah the specificity for 
endothelial cell.~, suggest that PD-ECGF may be useful as a therapeutic agent o stimulate re-endolhelialization m vtvo, or, in vtcw of its thym~dine 
phosphoryla~e activity, in chemotherapy, bydecrcasmg the pool of available thymidine. 
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1. INTRODUCTION 
Platelet-derived endothelial cell growth factor (PD- 
ECGF) was initially purified from human platelets as 
a 45 kDa protein [1] and was recently shown to form 
homodimers [2]. It stilnulates chemotaxis of endothelial 
cells in vitro and has angiogenic activity in vivo [3]. 
PD-ECGF is also present in human placenta [4]; in 
additiom it is produced by a limited number of normal 
and transformed cell lines in culture [5]. Cloning of its 
complementary DNA revealed that PD-ECGF lacks a 
hydrophobic leader sequence [3]. Consistent with this 
observation PD-ECGF is secreted from the producer 
cells only slowly [5]. More r~.,.ently, PD-ECGF was 
found to have sequence homology to Escherichia coli 
thymidine phosphorylase [6] and to have thymidine 
phosphorylase activity, i.e. catalyzing the reversible 
phosphorolysis of thymidine. PD-ECGF is therefore a 
human homologue of E. coli thymidine phosphoryiase 
[2]. The mechanism by which PD-ECGF exerts its ef- 
fects on endothelial ceils is unknown, but is likely to be 
indirect and i~volve products of its enzymatic activity. 
The availability of  a eDNA clone made it possible to 
produce recombinant haman PD-ECGF with full b;o- 
logical activity (unpublished results). Therefore° mate- 
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rial is now available for studies of the in "Avo effects of 
PD-ECGF when administered to the whole organism. 
In this report we de.~eribe the pharmacokinetics and 
organ distribution of PD-ECGF in the rat after intra~:e- 
nous injection. 
2. MATERIALS AND METHODS 
2.1. lodmation of t ecotttbiltant hutnarl PD-ECGF 
Recombinant human PD-ECGF (a kind gift from A. Thomason, 
Aragon Inc, Thousand Oak~, CA) w:t., ~-~1 labeled u~in~ the procedure 
described by Bolton and Hunter [7] with slight modifications. Tt~e 
resulting preparation had a ~pectfic radtoacttvay of 1/~Ci//~g. After 
this procedure PD-ECGF retains full biological activity m a [al-l]thy- 
midine incorporation assay in endothehal cells (data not shown). 
2.2 Ewertttterltal models attd assays 
Anixnal experiment~ were conducted using male Wlstar- Kyoto rats 
wetghmg about 200 g. Animals were anesthetized v, ah air mtraperi- 
toneal injectton of chloral hydrate (350 mNkg) and p la id  upon a 
hea}m~ plate (37°C) to prevent hypothermm. [~'~I]PD-ECGF (about 
0 5/aCt in 0.3 ml phosphate buffeted t~aline, ct~ntainmg Img gelatm 
per ml) was injected into each animal through a right jugular veto 
catheter, and blood ~amples of 0.2-0.3 ml were withdrawn after differ- 
ent time periods via a heparinized left carotid artery catheter Blood 
coagulation was prevented by EDTA in the precoateJ sampling tubes 
and plasma was prepared by separatton of blood cells by centrit'ug.a- 
tion for 2 mm at |0,0O0 × g. The radioactivity in whole blood az ¢¢ell 
a~ in plasma and m red blood ¢ell.~ (after removal of the buff), coat) 
wa~ determined ina y.counter The name was done w~tl't b~le and urine 
after collection throvgh additional catheters placed :n the common 
bile duct and the u, inary bladder The extent of degradation of the 
labeled material in the various liquid ~amples was determined by 
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preelpltation in 10% i~-cold tri~hloroacetie acid (TCA) on 3MM 
Whatman paper In addition, the samples were analyzed by SDS-gel 
¢lectrophorems (Pha~t-System, Pharmacm LKB, Uppnata, Sweden) 
and autoradloglaphy 3 h after the injection of the labeled material, 
tile ammals were sacrificed by an intravenous overdose of the anes- 
thetic, vanou~ organ~ were taken out and their wet weight and their 
content of ~-'~I radioaetw~ty determined The plasma weight was esti- 
mated by the use of normauve data [8], and its content of ~-~sI radioae. 
tivity was calculated by including the bamplgs withdrawn during the 
e:(periment. All animal work was performed in accordance with mstt- 
rational guidelines 
As a further test of its stability in rat serum, [t'Sl]PD-ECGF (about 
1 g~Ci m 0.25 ml of the buffer described above) was added to 1 ml of 
hepannized rat blood and incubated at 37°C, Samples were taken 
during a 6-h period and analyzed by y-seintillatlon a d by SDS-gel 
eleetrophorems and autoradiography. Determination f '-'~1 radioac- 
uvity in blood, bile, urine and tissue ~amples wab performed by T" 
scintillation (PW4800, Philips, The Netherlands) Unless l'urrl~er spec. 
~fied, all data represent the average of tnpheates __.S.E.M. 
Plasma clearance kmet~cs ofTCA-msoluble ~"-~1 rad~oaetlwty ere 
estimated using a two-compartment, non-linear regression model 
(PCNONLIN, Statistical Consultants, Lexington. KY) 
. | - -  
3. RESULTS 
3.1. PharmacoMnetics 
The rate of  disappearance of PD-ECGF from the 
blood and its components was studied in a rat model in 
which [~2sI]PD-ECGF was injected into the jugular vein, 
and blood samples were taken after differmtt ime peri- 
ods. [t2~I]PD-ECGF showed a biphasic clearance from 
the circulation of  the rat; an initial rapid clearance from 
the plasma (as well as from the whole blood) was fol- 
lowed by a slower phase. The estimated half-life for the 
initial distributior~ phase is 17 rain, whereas the value 
for the elimination phase is 7 h (Fig. 1), All radioactivity 
was precipitable by TCA. More than 90% of the radio- 
activity in the blood was restricted to the plasma 
throughout he whole experiment (one time point is 
shown in Fig. 2). No major degradation product was 
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FIg. 1. Disappearance oI'[I-'~I]PD-ECGF radioactivity from the circu- 
lation of rats. [="-=I]PD-ECGF (0.5/~Ci) was administered mtrave. 
,~oa~ly and zan~ples (0.2 ml) w.~fe takg,~ at d£iT¢lgJ~t tm£e polio. TCA 
prccipitable radioagtivlty was determined and is shown for the pla~:na 
fraciions. Results represent mean ~ S.E,M. from 3 different 
ezp~rlRl¢ll iS. 
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Organ d+.~tribalion of ~1 radioactivity p~r volume ur wet 
weight (¢pm/ml or cpm/g) after intravenous admmmtratJon of 0.5/tCl 
[J:~IIPD-ECGF into two male rats weighmg 194 and 209 g. Tissues 
were taken 3 h after injection of the labeled muterml. 
detected uring the time--course of  the experiment in 
which plasma was analyzed by SDS-gel electrophoresis 
and autoradiography (data not shown). 
The stability of PD-ECGF in vitro was further tested 
by incubation of  [~2~I]PD-ECGF in rat blood. Over a 
6-h period the TCA-precipitable ~251 radioactivity re- 
mained constant. Analysis of the plasma by SDS-gel 
eleetrophoresis and autoradiography demonstrated a 
45 kDa band, representing []25I]PD-ECGF. The inten- 
sity of  this band did not change during the 6-h period, 
nor did any degradation product occur (data not 
shown). 
3.2. Ocean distribution and degl'adation 
Three hours alter injection of [125I]PD-ECGF animals 
were sacritieed and the content o f  J2~I radioactivity in 
various organs and body fluids determined. The highest 
concentration of  radioactivity was still present in the 
blood and mainly restricted to the plasma (Table I). 
Comparing the radioactivity per wet weight or vol- 
ume there was no accumulation detected in any of  the 
organs analyzed (Fig. 2). Among the different organ 
systems, the liver plus bile contained the highest concen- 
tration of radioactivity. One hour after injection of  the 
labeled protein, high concentrations of radioactivity ap- 
peared in the bile, of which less than 10% was precipita- 
big by TCA. Fig. 3 shows an example for the appear- 
ance of radioactivity in the bile collected over three 
consecutive 60-rain intervals. Another animal showed a 
similar pattern, but had a lower bile production and a 
lower concentration of radioactivity during the ob- 
served period of time. Thus, our data indicate that 
[L~-~I]PD-ECGF is taken up by the liver, degraded and 
then excreted via the bile. There was no activity detected 
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Table I
Distribution of L:~I radtoactlwty invarious compartlnent~ of the body 
compared to their relatwe weitqhts 
Olgan % o1" m3ected radioactivity % or body weight 
Plasma 36.3 ± 4.0 4.0 +_ 0 
Lwer + bile 16.0 ± 2.7 3.6 + 0 
Othcr~ (rest) 47,7 +_ 2,0 92 4 __. 0 
Total recovery ~ 1 O0 100 
Sample~ were analyzed 3 h al'tel injection o1'0 5 HC~ of[~:~I]PD-ECGF 
(10 6 cprn) into rats. Results represent mean +_ S E.M. Item 3 different 
expcnments. 
in the urine during the time-course of the experiment 
(data not shown). 
4. DISCUSSION 
Using rat as a model we have shown that intrave- 
nously administered PD-ECGF disappears h'om the 
plasma with a fairly long half-life of about 7 h in the 
elimination phase. It is not accumulated in any organ 
system and the organ distribution largely reflects the 
blood content of the various tissues. One exception is 
the hepatobiliary s stem, where PD-ECGF is processed 
into non-TCA-precipitable molecules and excreted 
through the bile. 
Compared to other peptide growth factors present in 
platelets, such as platelct-derived growth factor 
(PDGF) and transforming rowth factor-/~ (TGF-/~), 
PD-ECGF has a much longer half-life in the plasma. 
PDGF has a halt-life of 2 rain, when injected into nor- 
mal baboons [9] and 5 rain in rats [10]. The rapid disap- 
pearance from the blood cam to a large extent, be ex- 
plained by binding to the serum protease inhibitor ¢x~_- 
maeroglobulin [11], which is rapidly cleared from the 
circulation by binding to hepatocytes [12]. TGF-fl has 
a o, imilar half-life of 2.2 rain in rats [13] and is cleared 
in the same way as PDGF by binding to cx~-macroglob- 
ulin [14,15]. In contrast, recombinant latent TGF-fl 
does not associate with 0:2-macroglobulin a d has an 
extended plasma half-life of slightly more than 100 rain 
in rats [16], which is somewhat closer to that which we 
determined for PD-ECGF. 
The long plasma half-life of PD-ECGF has important 
physiological implications. PD-ECGF might stimulate 
endothelial regeneration of' large vessels, and when re- 
leased from platelets or other producer cells, the biolog- 
ically active molecule may be carried by the circulation 
to distant arget cells. 
The lack of the hydrophobic leader sequence and the 
comparably long plasma halt-life of PD-ECGF, to- 
gether with the fact that PD-ECGF is not accumulated 
in any organ system other than the liver, where it is 
processed and eliminated from the cir~;ulation, are com- 
patible with the idea that PD-ECGF functions as a 
thymidine phosphorylase in rive. The thymidine 
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Fig, 3 Total and TCA-preeqmable '2~1 radloactiw:y m the bde accu- 
mulated over three con~ecuuve 60 min ume penodn after intravenous 
administration of 0.5/~Ci ["~I]PD-ECGF into a rat. Bd¢ was eolh,'cted 
through a catheter placed in the common bile duet. The amount of bde 
collected uring each of the three 60 mm time pgnodn wa~ about 420 
,el. TCA prgc':pitation wa~ performed a~ described in sectmn 2. 
phosphorylase activity of PD-ECGF, however, is of po- 
tential therapeutic interest itself. Chemotherapy with 
nueleotide analogues i based on the concept of incor- 
poration of modified nucleotides (instead of thymidine) 
into the DNA or RNA, resulting in the distortion of 
fundamental cellular mechanisms such as DNA replica- 
tion, transcription or translation. The thymidine 
phosphoryla~e activity of PD-ECGF could be useful in 
combination with nueleotide analogues to decrease the 
pool of available thymidine and to consecutively in- 
crease the incorporation rate of the analogue, and thus 
the efficacy of the chemotherapy. 
So far nothing is known about biological effects 
caused by systemically administered PD-ECGF. The 
long plasma half-life, however, would enable the factor 
to act within the circulatory system for several hours 
after the injection of a single dose. Furthermore, it will 
be possible to maintain a certain plasma level by appli- 
cation of a few doses per day. This makes PD-ECGF 
a suitable candidate tbr in rive studies, e.g. for stimula- 
tion of  re-endothelialization after pereutaneous translu- 
minal angioplasty of atheroselerotic vessels, where en- 
dothelial denudation and insufficient regeneration 
might be a reason lbr the rapid development of resten- 
osis (reviewed by [17]). Moreover, it will now be possi- 
ble to investigate whether PD-ECGF is useful in chemo- 
therapy, based on its thymidine phosphorylase activity. 
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